The hepatitis C virus protein NS3 suppresses TNF-α-stimulated activation of NF-κB by targeting LUBAC

Science Signaling

Volumn 8, Issue 403, 2015, Pages

  Chen, Yongzhi ^a,b   He, Liang ^a,b   Peng, Yanan ^a,b   Shi, Xiaodong ^a   Chen, Jizheng ^c   Zhong, Jin ^d   Chen, Xinwen ^c   Cheng, Genhong ^a,e   Deng, Hongyu ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c WUHAN INSTITUTE OF VIROLOGY   (China)

^d INSTITUTE PASTEUR OF SHANGHAI   (China)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LINEAR UBIQUITIN CHAIN ASSEMBLY COMPLEX; NONSTRUCTURAL PROTEIN 3; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; UNCLASSIFIED DRUG; NS3 PROTEIN, HEPATITIS C VIRUS; TUMOR NECROSIS FACTOR; VIRAL PROTEIN;

ARTICLE; CONTROLLED STUDY; GENE ACTIVATION; GENE REPRESSION; GENE TARGETING; HEPATITIS C; HEPATITIS C VIRUS; HOST CELL; HUMAN; HUMAN CELL; INNATE IMMUNITY; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; UBIQUITINATION; VIRUS REPLICATION; VIRUS SURVIVAL; HEK293 CELL LINE; METABOLISM; PHYSIOLOGY;

HEK293 CELLS; HUMANS; NF-KAPPA B; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITINATION; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84947764598     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aab2159     Document Type: Article

References (48)

1. H. Wajant, P. Scheurich, TNFR1-induced activation of the classical NF-κB pathway. FEBS J. 278, 862-876 (2011).
2. H. Walczak, TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunol. Rev. 244, 9-28 (2011).
3. B. Razani, G. Cheng, NF-κB: Much learned, much to learn. Sci. Signal. 3, pe29 (2010).
4. K. Iwai, Diverse ubiquitin signaling in NF-κB activation. Trends Cell Biol. 22, 355-364 (2012).
5. X. M. Jiang, Z. J. Chen, The role of ubiquitylation in immune defence and pathogen evasion. Nat. Rev. Immunol. 12, 35-48 (2012).
6. J. Chen, Z. J. Chen, Regulation of NF-κB by ubiquitination. Curr. Opin. Immunol. 25, 4-12 (2013).
7. K. Iwai, F. Tokunaga, Linear polyubiquitination: A new regulator of NF-κB activation. EMBO Rep. 10, 706-713 (2009).
8. C. H. Emmerich, A. C. Schmukle, H. Walczak, The emerging role of linear ubiquitination in cell signaling. Sci. Signal. 4, re5 (2011).
9. F. Tokunaga, S.-i. Sakata, Y. Saeki, Y. Satomi, T. Kirisako, K. Kamei, T. Nakagawa, M. Kato, S. Murata, S. Yamaoka, M. Yamamoto, S. Akira, T. Takao, K. Tanaka, K. Iwai, Involvement of linear polyubiquitylation of NEMO in NF-κB activation. Nat. Cell Biol. 11, 123-132 (2009).
10. T. L. Haas, C. H. Emmerich,B. Gerlach, A. C. Schmukle, S. M. Cordier, E. Rieser, R. Feltham, J. Vince, U. Warnken, T. Wenger, R. Koschny, D. Komander, J. Silke, H. Walczak, Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol. Cell 36, 831-844 (2009).
11. T. Kirisako, K. Kamei, S. Murata, M. Kato, H. Fukumoto, M. Kanie, S. Sano, F. Tokunaga, K. Tanaka, K. Iwai, A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J. 25, 4877-4887 (2006).
12. J. Niu, Y. Shi, K. Iwai, Z.-H. Wu, LUBAC regulates NF-κB activation upon genotoxic stress by promoting linear ubiquitination of NEMO. EMBO J. 30, 3741-3753 (2011).
13. A. Ehrlund, E. H. Anthonisen, N. Gustafsson, N. Venteclef, K. Robertson Remen, A. E. Damdimopoulos, A. Galeeva, M. Pelto-Huikko, E. Lalli, K. R. Steffensen, J. Å. Gustafsson, E. Treuter, E3 ubiquitin ligase RNF31 cooperates with DAX-1 in transcriptional repression of steroidogenesis. Mol. Cell. Biol. 29, 2230-2242 (2009).
14. M. Zhang, Y. Tian, R.-P. Wang, D. Gao, Y. Zhang, F.-C. Diao, D.-Y. Chen, Z.-H. Zhai, H.-B. Shu, Negative feedback regulation of cellular antiviral signaling by RBCK1-mediated degradation of IRF3. Cell Res. 18, 1096-1104 (2008).
15. K. Iwai, H. Ishikawa, T. Kirisako, Identification, expression, and assay of an oxidationspecific ubiquitin ligase, HOIL-1. Methods Enzymol. 398, 256-271 (2005).
16. F. Liu, Y. F. Xia, A. S. Parker, I. M. Verma, IKK biology. Immunol. Rev. 246, 239-253 (2012).
17. F. Tokunaga, K. Iwai, LUBAC, a novel ubiquitin ligase for linear ubiquitination, is crucial for inflammation and immune responses. Microbes Infect. 14, 563-572 (2012).
18. F. Tokunaga, T. Nakagawa, M. Nakahara, Y. Saeki, M. Taniguchi, S.-i. Sakata, K. Tanaka, H. Nakano, K. Iwai, SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex. Nature 471, 633-636 (2011).
19. F. Ikeda, Y. L. Deribe, S. S. Skånland, B. Stieglitz, C. Grabbe, M. Franz-Wachtel, S. J. van Wijk, P. Goswami, V. Nagy, J. Terzic, F. Tokunaga, A. Androulidaki, T. Nakagawa, M. Pasparakis, K. Iwai, J. P. Sundberg, L. Schaefer, K. Rittinger, B. Macek, I. Dikic, SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis. Nature 471, 637-641 (2011).
20. B. Gerlach, S. M. Cordier, A. C. Schmukle, C. H. Emmerich, E. Rieser, T. L. Haas, A. I.Webb, J. A. Rickard, H. Anderton, W. W.-L. Wong, U. Nachbur, L. Gangoda, U. Warnken, A. W. Purcell, J. Silke, H. Walczak, Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 471, 591-596 (2011).
21. C. W. Shepard, L. Finelli, M. J. Alter, Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5, 558-567 (2005).
22. B. D. Lindenbach, C. M. Rice, Unravelling hepatitis C virus replication from genome to function. Nature 436, 933-938 (2005).
23. K. D. Raney, S. D. Sharma, I. M. Moustafa, C. E. Cameron, Hepatitis C virus nonstructural protein 3 (HCV NS3): A multifunctional antiviral target. J. Biol. Chem. 285, 22725-22731 (2010).
24. M. Otsuka, N. Kato, M.Moriyama, H. Taniguchi, Y.Wang, N.Dharel, T. Kawabe, M.Omata, Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses. Hepatology 41, 1004-1012 (2005).
25. X. D. Li, L. Sun, R. B. Seth, G. Pineda, Z. J. Chen, Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl. Acad. Sci. U.S.A. 102, 17717-17722 (2005).
26. K. Li, E. Foy, J. C. Ferreon, M. Nakamura, A. C. M. Ferreon, M. Ikeda, S. C. Ray, M. Gale Jr., S. M. Lemon, Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. U.S.A. 102, 2992-2997 (2005).
27. E. Meylan, J. Curran, K. Hofmann, D. Moradpour, M. Binder, R. Bartenschlager, J. Tschopp, Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167-1172 (2005).
28. Y.-M. Loo, D. M. Owen, K. Li, A. K. Erickson, C. L. Johnson, P. M. Fish, D. S. Carney, T. Wang, H. Ishida, M. Yoneyama, T. Fujita, T. Saito, W.M. Lee, C. H. Hagedorn, D. T.-Y. Lau, S. A. Weinman, S. M. Lemon, M. Gale Jr., Viral and therapeutic control of IFN-β promoter stimulator 1 during hepatitis C virus infection. Proc. Natl. Acad. Sci. U.S.A. 103, 6001-6006 (2006).
29. H. Tilg, A.Wilmer, W. Vogel, M. Herold, B. Nölchen, G. Judmaier, C. Huber, Serum levels of cytokines in chronic liver diseases. Gastroenterology 103, 264-274 (1992).
30. D. Torre, C. Zeroli, M. Giola, G. Ferrario, G. P. Fiori, G. Bonetta, R. Tambini, Serum levels of interleukin-1α, interleukin-1β, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis. Clin. Infect. Dis. 18, 194-198 (1994).
31. M. Frese, K. Barth, A. Kaul, V. Lohmann, V. Schwärzle, R. Bartenschlager, Hepatitis C virus RNA replication is resistant to tumour necrosis factor-α. J. Gen. Virol. 84, 1253-1259 (2003).
32. L. Frelin, E. D. Brenndörfer, G. Ahlén, M. Weiland, C. Hultgren, M. Alheim, H. Glaumann, B. Rozell, D. R. Milich, J. G. Bode, M. Sällberg, The hepatitis C virus and immune evasion: Non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor a mediated liver disease. Gut 55, 1475-1483 (2006).
33. R. E. Lanford, B. Guerra, H. Lee, D. R. Averett, B. Pfeiffer, D. Chavez, L. Notvall, C. Bigger, Antiviral effect and virus-host interactions in response to a interferon, g interferon, poly(I)- poly(C), tumor necrosis factor a, and ribavirin in hepatitis C virus subgenomic replicons. J. Virol. 77, 1092-1104 (2003).
34. J. J. Lasarte, P. Sarobe, P. Boya, N. Casares, L. Arribillaga, A. López-Díaz de Cerio, M. Gorraiz, F. Borrás-Cuesta, J. Prieto, A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage. Hepatology 37, 461-470 (2003).
35. J. Zhong, P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, F. V. Chisari, Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U.S.A. 102, 9294-9299 (2005).
36. T.Wakita, T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H.-G. Kräusslich, M. Mizokami, R. Bartenschlager, T. J. Liang, Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791-796 (2005).
37. B. D. Lindenbach,M. J. Evans, A. J. Syder, B.Wölk, T. L. Tellinghuisen, C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, C. M. Rice, Complete replication of hepatitis C virus in cell culture. Science 309, 623-626 (2005).
38. Q. Han, C. Xu, C. Wu, W. Zhu, R. Yang, X. Chen, Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus. Virus Res. 145, 63-73 (2009).
39. C. S. Kim, J. H. Jung, T. Wakita, S. K. Yoon, S. K. Jang, Monitoring the antiviral effect of a interferon on individual cells. J. Virol. 81, 8814-8820 (2007).
40. D. M. Jones, S. N. Gretton, J. McLauchlan, P. Targett-Adams, Mobility analysis of an NS5A-GFP fusion protein in cells actively replicating hepatitis C virus subgenomic RNA. J. Gen. Virol. 88, 470-475 (2007).
41. J. Park, W. Kang, S.-W. Ryu, W.-I. Kim, D.-Y. Chang, D. H. Lee, D. Y. Park, Y.-H. Choi, K. Choi, E.-C. Shin, C. Choi, Hepatitis C virus infection enhances TNFα-induced cell death via suppression of nuclear factor-κB. Hepatology 56, 831-840 (2012).
42. G. Waris, A. Livolsi, V. Imbert, J.-F. Peyron, A. Siddiqui, Hepatitis C virus NS5A and subgenomic replicon activate NF-κB via tyrosine phosphorylation of IκBα and its degradation by calpain protease. J. Biol. Chem. 278, 40778-40787 (2003).
43. T. Kanda, R. Steele, R. Ray, R. B. Ray, Small interfering RNA targeted to hepatitis C virus 5′ nontranslated region exerts potent antiviral effect. J. Virol. 81, 669-676 (2007).
44. B. de Chassey, V. Navratil, L. Tafforeau, M. S. Hiet, A. Aublin-Gex, S. Agaugué, G. Meiffren, F. Pradezynski, B. F. Faria, T. Chantier, M. Le Breton, J. Pellet, N. Davoust, P. E. Mangeot, A. Chaboud, F. Penin, Y. Jacob, P. O. Vidalain, M. Vidal, P. André, C. Rabourdin-Combe, V. Lotteau, Hepatitis C virus infection protein network. Mol. Syst. Biol. 4, 230 (2008).
45. H. Fujita, S. Rahighi, M. Akita, R. Kato, Y. Sasaki, S. Wakatsuki, K. Iwai, Mechanism underlying IκB kinase activation mediated by the linear ubiquitin chain assembly complex. Mol. Cell. Biol. 34, 1322-1335 (2014).
46. M. Joo, Y. S. Hahn, M. Kwon, R. T. Sadikot, T. S. Blackwell, J. W. Christman, Hepatitis C virus core protein suppresses NF-κB activation and cyclooxygenase-2 expression by direct interaction with IκB kinase β. J. Virol. 79, 7648-7657 (2005).
47. Y. Chen, S. Wang, Z. Yi, H. Tian, R. Aliyari, Y. Li, G. Chen, P. Liu, J. Zhong, X. Chen, P. Du, L. Su, F. X.-F. Qin, H. Deng, G. Cheng, Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms. Sci. Rep. 4, 7242 (2014).
48. L.-Y. Chen, D. Liu, S. Zhou, Telomere maintenance through spatial control of telomeric proteins. Mol. Cell. Biol. 27, 5898-5909 (2007).